Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Griseofulvin
Drug ID BADD_D01042
Description An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Indications and Usage For the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by Trichophyton or Microsporum fungi.
Marketing Status Discontinued; Prescription
ATC Code D01AA08; D01BA01
DrugBank ID DB00400
KEGG ID D00209
MeSH ID D006118
PubChem ID 441140
TTD Drug ID D0C1SF
NDC Product Code 0781-5514; 60264-310; 0472-0013; 64980-186; 62135-496; 62135-495; 64980-185; 64980-184; 0781-5515; 49452-3363; 42794-012; 62135-494
Synonyms Griseofulvin | Grisefuline | Gris-PEG | Gris PEG | GrisPEG | Grisactin | Fulvicin-U-F | Fulvicin U F | FulvicinUF | Grifulvin V
Chemical Information
Molecular Formula C17H17ClO6
CAS Registry Number 126-07-8
SMILES CC1CC(=O)C=C(C12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash pustular23.03.10.003; 11.01.12.0020.003837%
Skin exfoliation23.03.07.0030.002558%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 10.01.03.020; 11.07.01.0050.002558%
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Tubulointerstitial nephritis20.05.02.0020.005116%Not Available
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.0050.006395%Not Available
Protein urine present13.13.02.006--Not Available
Epigastric discomfort07.01.02.004--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Focal segmental glomerulosclerosis20.05.01.0030.003837%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.011511%Not Available
Candida infection11.03.03.021--
The 2th Page    First    Pre   2    Total 2 Pages